ATC | B/G | Ingredients | code | Registration Nb | Name | Dosage | Presentation | Form | Route | Agent | Laboratory | Country | Price | Pharmacist Margin | Stratum | Responsible Party Name | Responsible Party Country | Exch_date | %SUBSIDY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
J06BD01 | BioTech | Palivizumab - 50mg/0.5ml | 9302 | 129217/1 | SYNAGIS | 50mg/0.5ml | 1x0.5ml | Injectable solution | IM | Omnipharma | Boehringer Ingelheim Pharma GmbH & Co KG | Germany | 742,477 L.L | 10.71 | E1 | Abbvie Ltd | UK | 05/02/20 |
ATC | B/G | Ingredients | code | Registration Nb | Name | Dosage | Presentation | Form | Route | Agent | Laboratory | Country | Price | Pharmacist Margin | Stratum | Responsible Party Name | Responsible Party Country | Exch_date | %SUBSIDY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
J06BD01 | BioTech | Palivizumab - 50mg/0.5ml | 9302/945 | 129217/1 | SYNAGIS | 50mg/0.5ml | 1x0.5ml | Injectable solution | IM | Omnipharma | Boehringer Ingelheim Pharma GmbH & Co KG | Germany | 45,266,280 L.L | 10.71 | E1 | Abbvie Ltd | UK | 05/02/20 | 0 |